Adaptive Biotechnologies said on Tuesday that it has expanded its collaboration with Laboratory Corporation of America to provide greater access to its portfolio of immune-driven clinical diagnostic and research products.
The expanded partnership includes a commercial agreement for Adaptive’s ClonoSeq and ImmunoSeq assays, as well as a lab service agreement for the Seattle-based company’s T-Detect COVID test, a clinical T-cell-based test to confirm prior COVID-19 infection in patients. In a separate announcement on Tuesday, Adaptive said that it has launched the T-Detect COVID test.
Financial and other terms of the LabCorp deal were not disclosed.
The partners previously inked an agreement in May 2020 to provide blood collections services at about 2,000 LabCorp patient service centers for Adaptive’s ClonoSeq test, an FDA-cleared assay for minimal residual disease in select blood cancers. As a result of the expanded deal, patients will have access to blood collection services for both the ClonoSeq and T-Detect COVID tests at any LabCorp patient service center, Adaptive said.
LabCorp’s oncology sales force will promote ClonoSeq at hematology-oncology clinics in the US. In addition, Burlington, North Carolina-based LabCorp is preparing to perform T-Detect at a secondary site if and when the test receives Emergency Use Authorization from the US Food and Drug Administration.
LabCorp will also offer the ImmunoSeq and ImmunoSeq T-Map COVID assays as research-use-only test kits to its biopharmaceutical customers, Adaptive said.